Gleevec

Leukemia and Blood Cancers

Gleevec is used to treat several conditions affecting the blood and bone marrow, including:

• Chronic Myeloid Leukemia (CML): It is prescribed for adults and children with Philadelphia chromosome-positive CML in various stages, including newly diagnosed cases and those where other treatments have not worked.
• Acute Lymphoblastic Leukemia (ALL): It is used for adults and children with Philadelphia chromosome-positive ALL, often alongside other treatments like chemotherapy.
• Myelodysplastic or Myeloproliferative Diseases: It treats certain rare blood disorders associated with specific genetic rearrangements.
• Hypereosinophilic Syndrome (HES) and Chronic Eosinophilic Leukemia (CEL): It is used for conditions involving an overgrowth of eosinophils, a type of white blood cell.
• Systemic Mastocytosis: It is used for aggressive forms of this disorder that lack a specific genetic mutation.

Solid Tumors

This medication is also indicated for specific types of tumors, including:

• Gastrointestinal Stromal Tumors (GIST): Gleevec is used to treat GIST that is kit-positive and cannot be surgically removed or has spread. It is also used after surgery to reduce the risk of the tumor returning.
• Dermatofibrosarcoma Protuberans (DFSP): It is used for this rare skin cancer when it cannot be removed by surgery, has recurred, or has spread to other parts of the body.

Targeting Cancer Growth

Gleevec belongs to a class of drugs known as tyrosine kinase inhibitors. Unlike traditional chemotherapy, which affects all rapidly dividing cells, Gleevec is a targeted therapy designed to interfere with specific proteins that contribute to cancer growth.

How It Blocks Cancer Signals

In certain types of cancer, such as Philadelphia chromosome-positive chronic myeloid leukemia (CML), the body produces an abnormal protein called BCR-ABL. This protein acts like a switch that is stuck in the "on" position, signaling white blood cells to multiply uncontrollably. Gleevec works by:

• Binding to the protein: The drug attaches to the abnormal protein in cancer cells.
• Interrupting the signal: By blocking the protein's ability to transmit signals, Gleevec prevents the cells from receiving the message to grow and divide.
• Slowing progression: This action helps stop or slow the spread of cancer cells and may lead to the death of existing cancer cells.

Gleevec also targets other proteins, including KIT and PDGFR. By blocking these specific enzymes, the medication can also treat other conditions, such as gastrointestinal stromal tumors (GIST), by preventing the signals that cause those tumors to grow.

Common Side Effects

Many people taking Gleevec experience mild to moderate side effects. These may include:

• Nausea, vomiting, or diarrhea
• Muscle cramps or bone and joint pain
• Fatigue or tiredness
• Headache
• Skin rash
• Mild swelling, particularly around the eyes, hands, or feet

Serious Side Effects

Some side effects can be severe and require immediate medical care. Contact a healthcare provider if you experience:

• Severe fluid retention: Rapid weight gain, shortness of breath, or swelling of the abdomen.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or pain in the upper right stomach area.
• Low blood cell counts: Fever, chills, sore throat, or other signs of infection; unusual bruising or bleeding; or feeling very weak or tired.
• Heart problems: Chest pain, shortness of breath, or a fast or irregular heartbeat.
• Gastrointestinal issues: Severe stomach pain or bloody or black, tarry stools.
• Severe skin reactions: Blistering, peeling, or painful rashes.

Fluid Retention and Heart Issues

Severe fluid retention, or edema, can occur during treatment. This may manifest as swelling in the legs, around the eyes, or more seriously, as fluid accumulation in the lungs or abdomen. In some instances, this fluid buildup can lead to or worsen heart failure and other cardiac complications.

Liver and Kidney Health

This medication can cause liver damage, which may be severe or fatal in some cases. Healthcare providers typically perform liver function tests before starting the drug and at regular intervals during treatment. Kidney function should also be monitored, particularly in patients with pre-existing renal conditions, as the drug may affect kidney health.

Blood Cell Counts

Gleevec can significantly lower the levels of white blood cells, red blood cells, and platelets. This condition, known as myelosuppression, increases the risk of infection, anemia, and easy bruising or bleeding. Frequent blood tests are required to monitor these levels and determine if treatment adjustments are necessary.

Gastrointestinal and Skin Reactions

• Gastrointestinal perforation: There is a risk of developing a hole in the wall of the stomach or intestines, which requires immediate medical attention.
• Severe skin reactions: Serious dermatologic conditions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, have been reported.
• Hemorrhage: Severe bleeding can occur in various parts of the body, including the gastrointestinal tract.

Pregnancy and Growth

This drug can cause harm to a developing fetus. Effective contraception is recommended for individuals of reproductive potential during treatment and for a period after the final dose. In children, long-term use of this medication may lead to growth impairment, necessitating regular monitoring of height and developmental milestones.

Tumor Lysis Syndrome

In some patients, the rapid breakdown of cancer cells can cause tumor lysis syndrome, which leads to chemical imbalances in the blood that can affect kidney function and heart rhythm. Preventive measures and monitoring are often employed for those at high risk.

Pregnancy

Gleevec (imatinib) can cause harm to an unborn baby if taken during pregnancy. Clinical reports and animal studies indicate that exposure to this medication may lead to birth defects or pregnancy loss. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider.

Healthcare providers typically recommend that females who can become pregnant use effective birth control during treatment and for at least 14 days after the final dose. If a patient becomes pregnant while taking this medication, they should notify their doctor immediately.

Breastfeeding

Imatinib and its active components are known to pass into human breast milk. Because of the risk of serious side effects in a nursing infant, breastfeeding is not recommended while taking Gleevec. Most guidelines suggest waiting at least one month after the last dose before resuming breastfeeding.

Available Forms

Gleevec is supplied as film-coated tablets. This medication is taken orally.

Administration Details

The tablets are designed to be swallowed whole with a meal and a large glass of water to help prevent irritation. For patients who are unable to swallow the tablets, they may be dissolved in a glass of water or apple juice before consumption.

FDA Approval and Indications

Gleevec (imatinib) is a prescription medication that received its initial approval from the U.S. Food and Drug Administration (FDA) in 2001. It is approved to treat several specific cancers and blood-related conditions in both adults and children.

Approved indications include:

• Certain phases of chronic myeloid leukemia (CML).
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
• Myelodysplastic or myeloproliferative diseases (MDS/MPD) associated with specific gene re-arrangements.
• Aggressive systemic mastocytosis (ASM) without certain genetic mutations.
• Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL).
• Gastrointestinal stromal tumors (GIST) that are KIT-positive.
• Dermatofibrosarcoma protuberans (DFSP) that cannot be removed by surgery, has returned, or has spread.

Safety Monitoring

The FDA monitors the safety of Gleevec through various reporting systems. The medication does not currently have a boxed warning, which is the FDA's most serious type of warning, nor does it require a Risk Evaluation and Mitigation Strategy (REMS) program.

In 2018, the FDA identified a potential safety signal regarding the risk of aneurysm (a bulge in an artery wall) and artery dissection (a tear in an artery wall) associated with the use of imatinib. The FDA continues to evaluate adverse event reports to determine if further regulatory action or labeling changes are necessary.

Factors Influencing Cost

The price of Gleevec can vary based on several elements:

• Insurance Coverage: Most health insurance plans cover imatinib, the generic version of Gleevec. However, insurance companies may require prior authorization before they agree to pay for the brand-name version.
• Generic Availability: A generic version of Gleevec, called imatinib, is available. Generic medications usually cost significantly less than brand-name drugs while providing the same therapeutic benefits.
• Pharmacy and Dosage: The specific pharmacy used and the dosage strength prescribed by a doctor will also impact the final cost.

Financial Assistance Programs

There are resources available to help manage the cost of this medication:

• Patient Assistance: Some manufacturers offer programs to provide the medication at a lower cost or for free to patients who meet specific financial criteria.
• Copay Cards: For patients with commercial insurance, copay savings cards may be available to reduce out-of-pocket expenses.
• Support Organizations: Certain non-profit organizations offer financial support to help patients cover the costs of cancer treatments.